NEWRON PHARMACEUTICALS S.P.A. EQS-Adhoc: Newron announces AGM 2021 result
Transparency directive : regulatory news
|
EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Miscellaneous Milan, Italy - April 13, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that its shareholders approved the sole motion on the agenda of the AGM 2021 held today, being the approval of the Company's balance sheet as of 31 December 2020 (including related and consequent resolutions). About Newron Pharmaceuticals For more information UK/Europe Switzerland Germany/Europe USA End of ad hoc announcement |
| Language: | English |
| Company: | Newron Pharmaceuticals SpA |
| Via Antonio Meucci 3 | |
| 20091 Bresso | |
| Italy | |
| E-mail: | info@newron.com |
| Internet: | www.newron.com |
| ISIN: | IT0004147952 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1184162 |
| End of Announcement | EQS Group News Service |
|
|
1184162 13-Apr-2021 CET/CEST